Rezza Giovanni
a Department of Infectious, Parasitic, and Immunomediated Diseases; Istituto Superiore di Sanità ; Roma , Italy.
Hum Vaccin Immunother. 2015;11(5):1258-60. doi: 10.1080/21645515.2015.1021528.
The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3 West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1 studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola.
2014年埃博拉疫情肆虐3个西非国家,其规模史无前例,对公共卫生应对能力构成了挑战,并促使人们需要有安全有效的疫苗。在此背景下,已在动物模型中进行过测试的载体疫苗已进入人体1期研究阶段,目前已准备好在大规模试验中进行疗效评估。医护人员和其他一线护理人员很可能是疫苗试验和疫苗接种运动的目标人群。然而,在有关开展临床试验以及可能使用已获许可的埃博拉疫苗的计划中,应考虑方法学和伦理问题。